

## COMPOUNDED SUBLINGUAL ORAL SEMAGLUTIDE

### How to Prescribe

1. Call us! Call in the prescription to one of our pharmacists on staff. Call 501-225-2222. Choose option 0.
2. Use the attached form to fax back to us
3. Electronic Prescription
  - a. Identify Don's Pharmacy as the desired pharmacy in EMR system
    - i. Phone number: 501-225-2222
    - ii. Address: 8609 W. Markham St. Suite A, Little Rock, AR 72205
    - iii. NPI: 1497869697
    - iv. NCPDP: 0401175
  - b. Select the medication
    - i. If your EMR system allows you to free-form a compounded medication that does not have a single-number NDC, consider free-form typing "Compounded Semaglutide 1mg-1ml in SubMagna™ HMW" as the prescribed medication.
    - ii. If your EMR system does NOT allow you to free-form a compounded medication, consider selecting RYBELSUS® 14mg Tablet and adding the clarification for the specific medication prescribed in the SIG or Prescription Direction Field as described below in #3.
  - c. Add the Directions or "SIG" (Use to Embed Compound Name and Compound Directions – Pick One)
    - i. Option 1: Write into notes: "Compounded Semaglutide Sublingual 13-Week Protocol." This includes the following:
      - 1st fill: Semaglutide 1mg/ml Suspension Place 0.5ml under the tongue for a minimum of 2 minutes once daily for 2 weeks then increase to 1ml once daily. Do not eat or drink anything for 30 minutes after dose
      - 2nd fill: Semaglutide 2mg/ml Suspension Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after dose
      - 3rd fill: Semaglutide 3mg/ml Suspension Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after doseMaintain dosage of 3mg daily thereafter
    - ii. Option 2: Compounded Semaglutide 1mg-1ml in SubMagna™ HMW – Once OR twice daily, place \_\_\_\_\_ml under tongue for a minimum of 2 minutes before swallowing. Do not eat or drink for 30 minutes after taking.
  - d. Select quantity in 30 mL increments
  - e. Enter number of authorized refills

No compounded medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. The FDA does not review any compounded medication from any pharmacy for safety or efficacy. RYBELSUS®, WEGOVY®, and OZEMPIC® are registered trademarks of Novo Nordisk A/S. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

**COMPOUNDED SUBLINGUAL ORAL SEMAGLUTIDE**

Return fax to 501-225-8683

**Patient Information**

Name: \_\_\_\_\_

DOB: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

Phone: \_\_\_\_\_

Allergies: \_\_\_\_\_

**Prescriber Information**

Name: \_\_\_\_\_

NPI: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

**PRESCRIPTION**

\_\_\_\_\_ 13-Week Protocol: This protocol is based on patient feedback and response to get patients to an effective maintenance dose efficiently.

1st fill: Semaglutide 1mg/ml Suspension Place 0.5ml under the tongue for a minimum of 2 minutes once daily for 2 weeks then increase to 1ml once daily. Do not eat or drink anything for 30 minutes after dose

2nd fill: Semaglutide 2mg/ml Suspension Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after dose

3rd fill: Semaglutide 3mg/ml Suspension Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after dose Maintain dosage of 3mg/ml daily thereafter

\_\_\_\_\_ **Other:** Once OR twice (circle one) daily, place \_\_\_\_\_ml under tongue for a minimum of 2 minutes before swallowing. Do not eat or drink for 30 minutes after taking.

Qty (in 30ml increments): \_\_\_\_\_

Refill \_\_\_\_\_ times

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

No compounded medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. The FDA does not review any compounded medication from any pharmacy for safety or efficacy. RYBELSUS®, WEGOVY®, and OZEMPIC® are registered trademarks of Novo Nordisk A/S. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

## Why choose our compounded sublingual suspension?

User friendly: No more needles and injections

Daily dosing: Gives the patient more flexibility

Patient Safety: We use FDA approved semaglutide as the active ingredient in our compound

Many patients would prefer to avoid injections if possible, and there is an extremely low absorption of the oral tablets (less than 1% per the labeling for Rybelsus®).

The sublingual route of administration provided by our semaglutide suspension is particularly advantageous as it bypasses the gastrointestinal tract, thereby avoiding the potential degradation of the active pharmaceutical ingredient (API) and the variable absorption issues associated with oral ingestion. This is especially beneficial for Semaglutide, a medication used in the treatment of type 2 diabetes and obesity, as it ensures more consistent and reliable drug delivery, which is critical for maintaining the therapeutic efficacy of the medication.

Upon application under the tongue, the SubMagna™ SL HMW base interacts with saliva to form an emulsion, which enhances the solubility and dispersibility of semaglutide. The unique mucoadhesive properties of the base prolong the contact time between the medication and the mucosal tissues, potentially allowing for greater absorption of the API. This feature, combined with the permeation-enhancing effects of the base, facilitates the efficient delivery of Semaglutide into the bloodstream, which may lead to improved glycemic control in patients with type 2 diabetes and support weight management in individuals with obesity.

No compounded medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. The FDA does not review any compounded medication from any pharmacy for safety or efficacy. RYBELSUS®, WEGOVY®, and OZEMPIC® are registered trademarks of Novo Nordisk A/S. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.